The NEPTUNE triple-blind, active-placebo, adaptive, pragmatic, randomized trial aims to evaluate the effectiveness of a new intra-venous hydration strategy guided by left ventricular end-diastolic pressure (LVEDP), amount of contrast used, and baseline renal function, to prevent contrast-induced acute kidney injury (CI-AKI) and patient-oriented clinical endpoints in all-comer patients undergoing coronary angiogram and/or percutaneous coronary intervention (PCI).
Age ≥18 years;
Planned coronary angiogram and/or PCI;
Willingness to participate and to attend study visits;
Expected life expectancy ≥6 months.
Cardiogenic or non-cardiogenic shock at the time of the procedure;
Emergent procedures (e.g. STEMI);
Iodine-based contrast media received within 2 days;
Presence of Intra-Aortic Balloon Pump (IABP);
Montreal Heart Institute
Lead sponsor
Université de Montréal
Collaborator
Canadian Institutes of Health Research (CIHR)
Collaborator